Invasive aspergillosis: Diagnosis, prophylaxis and treatment

Current Opinion in Hematology

Volumn 15, Issue 6, 2008, Pages 586-593

  Del Bono, Valerio ^a   Mikulska, Małgorzata ^a   Viscoli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Allogeneic; Antifungal; Aspergillosis; Diagnosis; Hematopoietic stem cell transplantation

Indexed keywords

1 [3 [4 (4 CYANOPHENYL) 2 THIAZOLYL] 2 (2,5 DIFLUOROPHENYL) 2 HYDROXYBUTYL] 4 [1 [N METHYL N [3 [2 (METHYLAMINO)ACETOXYMETHYL] 2 PYRIDINYL]CARBAMOYLOXY]ETHYL] 1H 1,2,4 TRIAZOL 4 IUM CHLORIDE; ALBACONAZOLE; ALEMTUZUMAB; AMINOCANDIN; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIGEN; ANTINEOPLASTIC AGENT; BETA GLUCAN; CASPOFUNGIN; DACLIZUMAB; ECHINOCANDIN; FLUCONAZOLE; FUNGAL DNA; GALACTOMANNAN; GALACTOMANNAN ANTIGEN; ITRACONAZOLE; MICAFUNGIN; OMEPRAZOLE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; PYRROLE; RAVUCONAZOLE; STEROID; TAZOBACTAM; TRIAZOLE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANTIFUNGAL ACTIVITY; ANTIGEN DETECTION; ASPERGILLOSIS; ASPERGILLUS; BACTERIUM DETECTION; BLOOD SAMPLING; BODY FLUID; CANCER COMBINATION CHEMOTHERAPY; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG TOLERABILITY; EARLY DIAGNOSIS; ENZYME IMMUNOASSAY; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; LIVER TOXICITY; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELIABILITY; REVIEW; RISK FACTOR; SALVAGE THERAPY; THERAPY EFFECT;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MANNANS;

EID: 55149104363     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328311890c     Document Type: Review

References (92)

1. Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study: Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45:1161-1170. The authors describe IFI incidence in a large Italian cohort.
2. Labbe AC, Su SH, Laverdiere M, et al. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant 2007; 13:1192-1200.
3. Miyakoshi S, Kusumi E, Matsumura T, et al. Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases. Biol Blood Marrow Transplant 2007; 13:771-777.
4. Sinko J, Csomor J, Nikolova R, et al. Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey. Transpl Infect Dis 2008; 10:106-109.
5. Khayyata S, Soubani AO, Bonnett M, et al. The major autopsy findings in adult patients after hematopoietic stem cell transplantation. Ann Transplant 2007; 12:11-18.
6. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102:827-833.
7. Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002; 8:512-520.
8. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-415.
9. Post MJ, Lass-Floerl C, Gastl G, Nachbaur D. Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis 2007; 9:189-195.
10. Mihu CN, King E, Yossepovitch O, et al. Risk factors and attributable mortality of late aspergillosis after T-cell depleted hematopoietic stem cell transplantation. Transpl Infect Dis 2008; 10:162-167.
11. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008; 83:181-194.
12. Sainz J, Perez E, Hassan L, et al. Variable number of tandem repeats of TNF receptor type 2 promoter as genetic biomarker of susceptibility to develop invasive pulmonary aspergillosis. Hum Immunol 2007; 68:41-50.
13. Sainz J, Hassan L, Perez E, et al, Interleukin-10 promoter polymorphism as risk factor to develop invasive pulmonary aspergiltosis. Immunol Lett 2007; 109:76-82.
14. Kontoyiannis DP, Chamilos G, Lewis RE, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 2007; 110:1303-1306.
15. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
16. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-1821. An update on clinical definition criteria of IFI. Nonculture-based techniques are accepted as a microbiologic diagnostic criterion. Halo sign only is not considered as a definition of probable invasive aspergillosis.
17. Maertens J, Theunissen K, Lodewyck T, et al. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses 2007; 50 (Suppl 1):2-17.
18. Maertens JA, Klont R, Massen C, et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 2007; 44:1329-1336. This study reports the clinical usefulness of a lower cutoff for galactomannan antigen in hematologic patients.
19. Penack O, Rempf P, Graf B, et al. Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management. Ann Oncol 2008; 19:984-989.
20. Viscoli C, Machetti M, Cappellano P, et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38:913-916.
21. Asano-Mori Y, Kanda Y, Oshima K, et al. False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation. J Antimicrob Chemother 2008; 61:411-416.
22. Machetti M, Furfaro E, Viscoli C. Galactomannan in piperacillin- tazobactam: how much and to what extent? Antimicrob Agents Chemother 2005; 49:3984-3985.
23. Machetti M, Majabo MJ, Furfaro E, et al. Kinetics of galactomannan in surgical patients receiving perioperative piperacillin/tazobactam prophylaxis. J Antimicrob Chemother 2006; 58:806-810.
24. Cummings JR, Jamison GR, Boudreaux JW, et al. Cross-reactivity of non-Aspergillus fungal species in the Aspergillus galactomannan enzyme immunoassay. Diagn Microbiol Infect Dis 2007; 59:113-115.
25. Racil Z, Kocmanova I, Lengerova M, et al. Intravenous PLASMA-LYTE as a major cause of false-positive results of platelia Aspergillus test for galactomannan detection in serum. J Clin Microbiol 2007; 45:3141-3142.
26. Hage CA, Reynolds JM, Durkin M, et al. Plasmalyte as a cause of false-positive results for Aspergillus galactomannan in bronchoalveolar lavage fluid. J Clin Microbiol 2007; 45:676-677.
27. Steinbach WJ, Addison RM, McLaughlin L, et al. Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J 2007; 26:558-564. This study shows promising results of galactomannan use for invasive aspergillosis diagnosis in pediatric population.
28. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20:1898-1906.
29. Woods G, Miceli MH, Grazziutti ML, et al. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 2007; 110:830-834.
30. Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008; 46:1412-1422.
31. Winn RM, Warris A, Gaustad P, Abrahamsen TG. The effect of antifungal agents and human monocytes on in vitro galactomannan release by Aspergillus spp. in liquid culture medium. APMIS 2007; 115:1364-1369.
32. Persat F, Ranque S, Derouin F, et al. Contribution of the (1→3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2008; 46:1009-1013. This French retrospective study of 70 cases of pulmonary invasive aspergillosis reports higher rate of detection of pulmonary invasive aspergillosis with beta-glucan assay compared with galactomannan test.
33. Khan ZU, Ahmad S, Theyyathel AM. Detection of Aspergillus fumigatus-specific DNA, (1-3)-beta-D-glucan and galactomannan in serum and bronchoalveolar lavage specimens of experimentally infected rats. Mycoses 2008; 51:129-135.
34. Ahmad S, Khan ZU, Theyyathel AM. Diagnostic value of DNA, (1-3)-beta-D-glucan, and galactomannan detection in serum and bronchoalveolar lavage of mice experimentally infected with Aspergillus terreus. Diagn Microbiol Infect Dis 2007; 59:165-171.
35. Senn L, Robinson JO, Schmidt S, et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008; 46:878-885. This Swiss study of 190 consecutive neutropenic episodes reported promising results of use of beta-glucan with two consecutive values 7 pg/ml or more.
36. Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1→3)-beta-D-glucan assay for the diagnosis of invasive fungal infections: a study based on autopsy cases from 6 years. Clin Infect Dis 2008; 46:1864-1870. This study showed reliable results of beta-glucan test in proven invasive aspergillosis.
37. Mennink-Kersten MA, Warris A, Verweij PE. 1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med 2006; 354:2834-2835.
38. Pickering JW, Sant HW, Bowles CA, et al. Evaluation of a (1→3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43:5957-5962.
39. Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1,3-beta-d-glucan assay reactivity. Clin Infect Dis 2008; 46:1930-1931.
40. Spiess B, Seifarth W, Hummel M, et al. DNA microarray-based detection and identification of fungal pathogens in clinical samples from neutropenic patients. J Clin Microbiol 2007; 45:3743-3753.
41. Gomez-Lopez A, Martin-Gomez MT, Martin-Davila P, et al. Detection of fungal DNA by real-time polymerase chain reaction: evaluation of 2 methodologies in experimental pulmonary aspergillosis. Diagn Microbiol Infect Dis 2006; 56:387-393.
42. Cesaro S, Stenghele C, Calore E, et al. Assessment of the lightcycler PCR assay for diagnosis of invasive aspergillosis in paediatric patients with oncohaematological diseases. Mycoses 2008 [Published Online: Mar 4 2008].
43. Rickerts V, Mousset S, Umbrecht E, et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis 2007; 44:1078-1083. This study reports good performance of PCR on biopsy specimens.
44. Lass-Florl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007; 45:e101-e104. The authors report good results of computed tomography-guided pulmonary biopsy in invasive aspergillosis diagnosis, using PCR and galactomannan immunoassay.
45. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44:373-379. This is a report on pathogenesis and incidence of a halo sign. Patients presenting with a halo sign had significantly better responses to treatment. Was this due to earlier diagnosis or to poor diagnostic specificity and the fact that some patients with the halo sign only actually have another disease?
46. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26:781-803.
47. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19:253-259.
48. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347. This large randomized multicenter study showed efficacy of posaconazole in reducing incidence of fungal infections, although no benefit on survival rate was observed.
49. Comely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-359. This large randomized multicenter study in leukemia patients reported efficacy of posaconazole in reducing incidence of fungal infections. Survival was significantly longer among recipients of posaconazole than among recipients of fluconazole or itraconazole.
50. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007; 356:1481-1483.
51. Cordonnier C, Mohty M, Faucher C, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study, Int J Antimicrob Agents 2008; 31:135-141.
52. Rijnders BJ, Comelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46:1401-1408. These are encouraging results from a randomized placebo-controlled study of 271 patients during 407 neutropenic episodes. This new and promising prophylaxis regimen showed to be effective, without serious toxicity.
53. Ho KM, Duff O, Chambers D, Murray R. Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals. Transpl Infect Dis 2008; 10:168-176.
54. Vehreschild JJ, Bohme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007; 55:445-449.
55. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007; 40:451-456.
56. Wingard JR, Carter SL, Walsh TJ, et al. Results of a randomized, double-blind trail of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients [abstract #163]. In: Abstracts of The American Society of Hematology 49th Annual Meeting and Exposition, Atlanta, USA, Dec 2007.
57. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39:425-429.
58. Nosari A, Ravini M, Cairoli R, et al. Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia. Bone Marrow Transplant 2007; 39:631-635.
59. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-360. These are updated and comprehensive guidelines on treatment of aspergillosis.
60. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44:1289-1297. This study showed that high doses of liposomal amphotericin B are not significantly more effective than lower doses. Moreover, higher doses were associated with significantly higher toxicity rates.
61. Denning DW. Comparison of 2 studies of treatment of invasive aspergillosis. Clin Infect Dis 2007; 45:1106-1108; author reply 1108-1110.
62. Cordonnier C, Bresnik M, Ebrahimi R. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in irnmunocompromised hosts: a pooled analysis. Mycoses 2007; 50:205-209.
63. Viscoli C, Herbrecht R, Akan H, et al. Caspofungin (C) as a first-line therapy of invasive aspergillosis (IA) in haematological patients (pts): a study of the EORTC Infectious Diseases Group [abstract #0.12]. In: Abstracts of 3rd Trends in Medical Mycology, Turin, Italy, 2007.
64. Lewis RE, Liao G, Hou J, et al. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007; 51:1253-1258.
65. van de Sande WW, van Vianen W, Ten Kate MT, et al. Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2008; 52:1345-1350.
66. Lewis RE, Albert ND, Kontoyiannis DP. Comparison of the dose-dependent activity and paradoxical effect of Caspofungin and micafungin in a neutropenic murine model of Invasive pulmonary aspergillosis. J Antimicrob Chemother 2008;61:1140-1144.
67. Ullmann AJ, Krammes E, Sommer S, et al. Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats. J Antimicrob Chemother 2007; 60:1080-1084.
68. Nucci M, Perfect JR. When primary antifungal therapy fails. Clin Infect Dis 2008; 46:1426-1433.
69. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2-12. This open-label study including 107 patients in salvage treatment with posaconazole, demonstrated the success rate of 42% in posaconazole recipients versus 26% in controls. The study also showed a clear relationship between posaconazole blood levels and RR.
70. Hachem RY, Boktour MR, Hanna HA, et al. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer 2008; 112:1282-1287. This retrospective study confirms what is frequently observed in daily clinical practice: RR are poor in high-risk patients due to advanced stage and the severity of the underling diseases.
71. Herbrecht R, Flückigerb U, Gachotc B, et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur J Cancer Suppl 2007; 5:49-59.
72. Caillot D, Thiebaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007; 110:2740-2746.
73. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107:2888-2897.
74. Kaffarnik M, Utzolino S, Blaich A, Hopt UT. Successful multimodal therapy of invasive pulmonary and central nervous system aspergillosis in a neutropenic surgical patient: case report and review of the literature. Mycoses 2008; 51:74-78.
75. Eliashar R, Resnick IB, Goldfarb A, et al. Endoscopic surgery for sinonasal invasive aspergillosis in bone marrow transplantation patients. Laryngoscope 2007; 117:78-81.
76. Hope WW, Kruhlak MJ, Lyman CA, et al. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis 2007; 195:455-466.
77. Segal BH. Role of macrophages in host defense against aspergillosis and strategies for immune augmentation. Oncologist 2007; 12 (Suppl 2): 7-13.
78. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50:1570-1572.
79. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109:1532-1535.
80. Pascual A, Nieth V, Calandra T, et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother 2007; 51:137-143. This study highlighted voriconazole plasma levels variability, with possible clinical implications.
81. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201-211. This large clinical study, with a total of 181 HPLC measurements in 52 patients, documented a possible association between low voriconazole levels and clinical failure and high levels and neurotoxicity.
82. Langman LJ, Boakye-Agyeman F. Measurement of voriconazole in serum and plasma. Clin Biochem 2007; 40:1378-1385.
83. Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006; 136:739-742.
84. Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 2008; 61:17-25.
85. Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008; 61 (Suppl 1):i19-i30.
86. Guinea J, Pelaez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008; 52:1396-1400.
87. Kakeya H, Miyazaki Y, Senda H, et al. Efficacy of SPK-843, a novel polyene antifungal in murine pulmonary aspergillosis in comparison with amphotericin B, AmBisome and micafungin. Antimicrob Agents Chemother 2008; 52:1868-1870.
88. Petrikkos G, Skiada A. Recent advances in antifungal chemotherapy, Int J Antimicrob Agents 2007; 30:108-117.
89. Martin de la Escalera C, Aller Al, Lopez-Oviedo E, et al. Activity of BAL 4815 against filamentous fungi. J Antimicrob Chemother 2008; 61:1083-1086.
90. Upton A, Kirby KA, Carpenter P, et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44:531-540. This is a large retrospective study describing outcome in 405 patients with probable or proven invasive aspergillosis. In recent years, mortality rates were decreased, coinciding with improvements in transplantation practice.
91. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 2008; 112:2309-2312.
92. Lai CC, Liaw SJ, Lee LN, et al. Invasive pulmonary aspergillosis: high incidence of disseminated intravascular coagulation in fatal cases. J Microbiol Immunol Infect 2007; 40:141-147.